Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty

Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty

About this clinical trial

The number of people undergoing total knee arthroplasty (TKA) for osteoarthritis has been steadily increasing in Australia. There is a significant risk of blood loss during this procedure, resulting in prolonged hospital stay, pain and poor functional outcomes.

The purpose of this trial is to evaluate the effects of oral Tranexamic Acid (TXA) when administered pre-operatively.

Patients Required

Estimated completion

December 2023

Total participants required


Study location

The Wesley Hospital

Trial title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty


People undergoing primary unilateral Total Knee Arthroplasty.

Additional information

You can find out more about this clinical trial by visiting the ANZCTR website.

Lead investigator

Dr Sue Clark

If you would like more information about this clinical trial, please complete the TXA contact form


Wesley Medical Research

Scroll to Top